Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 66

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 66
---
, if applicable, a discussion of certain U.S. federal income tax and ERISA considerations.

Warrants for the purchase of preferred stock and
common stock will be offered and exercisable for U.S. dollars only.

Each warrant will entitle its holder to purchase
the principal amount of debt securities or the number of shares of preferred stock or common stock at the exercise price set forth in,
or calculable as set forth in, the applicable prospectus supplement.

<div align='center'>19</div>

After the close of business on the expiration
date, unexercised warrants will become void. We will specify the place or places where, and the manner in which, warrants may be exercised
in the applicable prospectus supplement.

Prior to the exercise of any warrants to purchase
debt securities, preferred stock or common stock, holders of the warrants will not have any of the rights of holders of the debt securities,
preferred stock or common stock purchasable upon exercise.

As of February 13, 2024, warrants to purchase
a total of 882,349 shares of common stock at a weighted average exercise price of $1.58 per share were outstanding. Warrants to purchase
a total of 597 shares of common stock expire in December 2024 and have an exercise price of $19.80 per share. Warrants to purchase a total
of 5,772 shares of common stock expire in December 2024 and have an exercise price of $17.40 per share. Warrants to purchase a total of
1,355 shares of common stock expire in December 2025 and have an exercise price of $17.50 per share. Warrants to purchase a total of 301,875
shares of common stock expire in November 2026 and have an exercise price of $1.50 per share. Warrants to purchase a total of 572,750
shares of common stock expire in May 2028 and have an exercise price of $ 1.40.

<div align='center'>DESCRIPTION OF
UNITS WE MAY OFFER</div>

We may issue units consisting of any combination
of the other types of securities offered under this prospectus in one or more series. We may evidence each series of units by unit certificates
that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or
trust company that we select. We will indicate the name and address of the unit agent in the